Abstract
A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent, topotecan, is presented. The model is a result of linking the pharmacokinetic (pK) and pharmacodynamic (pD) responses. By linking the models in this way, rather than using separate (static) approaches, it is possible to illustrate how the drug perturbs the cell cycle. The model is validated for a range of drug concentrations with experimental data.
Original language | English |
---|---|
Title of host publication | IFAC Proceedings Volumes |
Publisher | Elsevier |
Pages | 477-482 |
Number of pages | 6 |
Volume | 6 |
Edition | PART 1 |
ISBN (Electronic) | 9-783-9026-6118-0 |
DOIs | |
Publication status | Published - 2006 |
Externally published | Yes |
Event | 6th IFAC Symposium on Modeling and Control in Biomedical Systems - Reims, France Duration: 20 Aug 2006 → 22 Aug 2006 |
Publication series
Name | IFAC Proceedings Volumes |
---|---|
Publisher | Elsevier |
Number | 18 |
Volume | 39 |
ISSN (Print) | 1474-6670 |
Conference
Conference | 6th IFAC Symposium on Modeling and Control in Biomedical Systems |
---|---|
Abbreviated title | MCBMS 2006 |
Country | France |
City | Reims |
Period | 20/08/06 → 22/08/06 |
Fingerprint
Keywords
- Compartmental models
- Drug kinetics
- Pharmacodynamics
- Pharmacokinetics
- Topotecan
ASJC Scopus subject areas
- Control and Systems Engineering
Cite this
A PK-PD model of cell cycle response to topotecan. / Ali, R.; Campbell, L.; Evans, N. D.; Errington, R. J.; Godfrey, K. R.; Smith, P. J.; Chappell, M. J.
IFAC Proceedings Volumes. Vol. 6 PART 1. ed. Elsevier, 2006. p. 477-482 (IFAC Proceedings Volumes; Vol. 39, No. 18).Research output: Chapter in Book/Report/Conference proceeding › Conference proceeding
}
TY - GEN
T1 - A PK-PD model of cell cycle response to topotecan
AU - Ali, R.
AU - Campbell, L.
AU - Evans, N. D.
AU - Errington, R. J.
AU - Godfrey, K. R.
AU - Smith, P. J.
AU - Chappell, M. J.
PY - 2006
Y1 - 2006
N2 - A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent, topotecan, is presented. The model is a result of linking the pharmacokinetic (pK) and pharmacodynamic (pD) responses. By linking the models in this way, rather than using separate (static) approaches, it is possible to illustrate how the drug perturbs the cell cycle. The model is validated for a range of drug concentrations with experimental data.
AB - A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent, topotecan, is presented. The model is a result of linking the pharmacokinetic (pK) and pharmacodynamic (pD) responses. By linking the models in this way, rather than using separate (static) approaches, it is possible to illustrate how the drug perturbs the cell cycle. The model is validated for a range of drug concentrations with experimental data.
KW - Compartmental models
KW - Drug kinetics
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Topotecan
U2 - 10.3182/20060920-3-FR-2912.00085
DO - 10.3182/20060920-3-FR-2912.00085
M3 - Conference proceeding
VL - 6
T3 - IFAC Proceedings Volumes
SP - 477
EP - 482
BT - IFAC Proceedings Volumes
PB - Elsevier
ER -